JP2019529501A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019529501A5 JP2019529501A5 JP2019517823A JP2019517823A JP2019529501A5 JP 2019529501 A5 JP2019529501 A5 JP 2019529501A5 JP 2019517823 A JP2019517823 A JP 2019517823A JP 2019517823 A JP2019517823 A JP 2019517823A JP 2019529501 A5 JP2019529501 A5 JP 2019529501A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- thiolated
- nitrofatty
- kidney disease
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 11
- 229930195729 fatty acid Natural products 0.000 claims description 11
- 239000000194 fatty acid Substances 0.000 claims description 11
- -1 nitro fatty acid Chemical class 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims 17
- 239000002253 acid Substances 0.000 claims 11
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 4
- 208000008589 Obesity Diseases 0.000 claims 4
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 4
- 150000007513 acids Chemical class 0.000 claims 4
- 230000001154 acute effect Effects 0.000 claims 4
- 208000020832 chronic kidney disease Diseases 0.000 claims 4
- 208000017169 kidney disease Diseases 0.000 claims 4
- 235000020824 obesity Nutrition 0.000 claims 4
- RPAJSBKBKSSMLJ-DFWYDOINSA-N (2s)-2-aminopentanedioic acid;hydrochloride Chemical class Cl.OC(=O)[C@@H](N)CCC(O)=O RPAJSBKBKSSMLJ-DFWYDOINSA-N 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims 2
- 229910000037 hydrogen sulfide Inorganic materials 0.000 claims 2
- 230000004968 inflammatory condition Effects 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 102000005862 Angiotensin II Human genes 0.000 claims 1
- 101800000733 Angiotensin-2 Proteins 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 108010024636 Glutathione Proteins 0.000 claims 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000026072 Motor neurone disease Diseases 0.000 claims 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 150000001336 alkenes Chemical class 0.000 claims 1
- 229950006323 angiotensin ii Drugs 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000036523 atherogenesis Effects 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 230000001934 delay Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 210000002249 digestive system Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229960003180 glutathione Drugs 0.000 claims 1
- 230000007794 irritation Effects 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 230000008058 pain sensation Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 208000037905 systemic hypertension Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 125000000524 functional group Chemical group 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- 239000011593 sulfur Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 125000000213 sulfino group Chemical group [H]OS(*)=O 0.000 description 2
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662404368P | 2016-10-05 | 2016-10-05 | |
| US62/404,368 | 2016-10-05 | ||
| PCT/US2017/055149 WO2018067705A1 (en) | 2016-10-05 | 2017-10-04 | Reversibly protected thiolated electrophilic fatty acids as prodrugs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019529501A JP2019529501A (ja) | 2019-10-17 |
| JP2019529501A5 true JP2019529501A5 (enExample) | 2020-11-12 |
Family
ID=61832194
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019517823A Pending JP2019529501A (ja) | 2016-10-05 | 2017-10-04 | 可逆的に保護された、チオレート化求電子性脂肪酸としてのプロドラッグ |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US10744106B2 (enExample) |
| EP (1) | EP3522884B1 (enExample) |
| JP (1) | JP2019529501A (enExample) |
| CN (1) | CN109803648A (enExample) |
| CA (1) | CA3039376A1 (enExample) |
| ES (1) | ES2982757T3 (enExample) |
| WO (1) | WO2018067705A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019529517A (ja) | 2016-10-05 | 2019-10-17 | ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | ニトロソ化およびアルキル化反応を媒介するニトロアルケンの新規可逆的窒素酸化物誘導体 |
| WO2020102529A1 (en) | 2018-11-14 | 2020-05-22 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Electrophiles and electrophile pro-drugs as rad51 inhibitors |
| WO2021242758A1 (en) * | 2020-05-26 | 2021-12-02 | Imara Inc. | Improved nitro-fatty acid oral dose regimens |
| CN118845745B (zh) * | 2024-09-25 | 2024-12-17 | 浙江大学医学院附属第二医院 | 辛酸钠在制备治疗脓毒症药物中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8324277B2 (en) | 2007-08-01 | 2012-12-04 | University of Pittsburgh—of the Commonwealth System of Higher Education | Nitrated-fatty acids modulation of type II diabetes |
| WO2010014889A2 (en) | 2008-08-01 | 2010-02-04 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Nitro fatty acids as regiomers and related mimetics |
| JP2013500966A (ja) | 2009-07-31 | 2013-01-10 | ユニバーシティー オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション | 抗炎症剤としての脂肪酸 |
| US20150018417A1 (en) | 2012-02-03 | 2015-01-15 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Fatty acids as anti-inflammatory agents |
| JP6959246B2 (ja) | 2016-03-04 | 2021-11-02 | ユニバーシティ オブ ピッツバーグ−オブ ザ コモンウェルス システム オブ ハイヤー エデュケーションＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｐｉｔｔｓｂｕｒｇｈ Ｏｆ Ｔｈｅ Ｃｏｍｍｏｎｗｅａｌｔｈ Ｓｙｓｔｅｍ Ｏｆ Ｈｉｇｈｅｒ Ｅｄｕｃａｔｉｏｎ | 治療に有効な量のジカルボン酸化合物を使用した、病気の予防、治療及び治癒 |
| JP2019529517A (ja) | 2016-10-05 | 2019-10-17 | ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | ニトロソ化およびアルキル化反応を媒介するニトロアルケンの新規可逆的窒素酸化物誘導体 |
-
2017
- 2017-10-04 WO PCT/US2017/055149 patent/WO2018067705A1/en not_active Ceased
- 2017-10-04 CA CA3039376A patent/CA3039376A1/en active Pending
- 2017-10-04 CN CN201780062044.9A patent/CN109803648A/zh active Pending
- 2017-10-04 ES ES17859121T patent/ES2982757T3/es active Active
- 2017-10-04 JP JP2019517823A patent/JP2019529501A/ja active Pending
- 2017-10-04 US US16/339,702 patent/US10744106B2/en active Active
- 2017-10-04 EP EP17859121.0A patent/EP3522884B1/en active Active
-
2020
- 2020-07-23 US US16/937,263 patent/US20200352890A1/en not_active Abandoned
-
2023
- 2023-05-22 US US18/200,344 patent/US20230321022A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018518537A5 (enExample) | ||
| JP2019529501A5 (enExample) | ||
| JP2021063088A5 (enExample) | ||
| JP2013508279A5 (enExample) | ||
| JP2017537940A5 (enExample) | ||
| JP2019532928A5 (enExample) | ||
| JP2012512907A5 (enExample) | ||
| JP2013507439A5 (enExample) | ||
| UA107578C2 (uk) | Комбінована терапія при лікуванні діабету | |
| BRPI0820112B8 (pt) | derivados de isoxazol-piridina, seu uso e processos de preparação e medicamento | |
| JP2013518107A5 (enExample) | ||
| JP2020507589A5 (enExample) | ||
| JP2009504748A5 (enExample) | ||
| JP2019516739A5 (enExample) | ||
| JP2015508068A5 (enExample) | ||
| RU2008107733A (ru) | Ингибиторы gsk-3 | |
| JP2019520344A5 (enExample) | ||
| JP2019529541A5 (enExample) | ||
| JP2011088926A5 (enExample) | ||
| JP2007522162A5 (enExample) | ||
| JP2015516419A5 (enExample) | ||
| CY1109678T1 (el) | Νεα παραγωγα 3-φαινυλπροπιονικου οξεος και χρηση αυτων ως συνδετηρες του υποδοχεα ppar-γαμμα | |
| JP2009040767A5 (enExample) | ||
| RU2010148387A (ru) | Производное фенилпропионовой кислоты и его применение | |
| JP2010500284A5 (enExample) |